Intellia Therapeutics Announces US FDA Acceptance of Investigational New Drug Application for NTLA-5001, Its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia

Intellia Therapeutics, Inc. announced that the US FDA has accepted the investigational new drug application for NTLA-5001, the company’s first wholly-owned ex vivo CRISPR genome editing candidate for the treatment of cancer.